相关实验视频
Updated: May 20, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2024年临床心脏病学的进步:关键临床试验的总结
Patrick Savage1, Michael Campbell2, Meadhbh Hogg2
1Craigavon Cardiology Department, Southern Health & Social Care Trust, Craigavon, Northern Ireland, UK. psavage05@qub.ac.uk.
本综述总结了90多项关键的2024年心脏病学试验,突出了穿皮冠状动脉干预,结构性心脏干预和预防性心脏病学方面的进展,影响了临床实践.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 心血管医学 心血管医学
背景情况:
- 2024年,许多心脏病学关键临床试验被介绍或发表.
- 本综述将这些试验在其临床背景下进行整合和综合.
研究的目的:
- 从2024年开始对关键的临床心脏病学试验进行整理和总结.
- 思考这些试验对当前实践的临床意义和潜在影响.
主要方法:
- 在2024年在主要的国际心脏病学会议上提出的临床试验的系统审查.
- 包括标准集中在可能影响或改变临床实践的试验上.
主要成果:
- 超过90个重要的心脏病学试验在各种子专业领域被确定.
- 关键发现包括皮肤冠状动脉干预 (PCI) 的更新,结构性心脏干预 (TAVR,三管,双管) 和预防性心脏病学 (脂蛋白),LDL,高血压,心力衰竭,多变性心肌病,心脏 Amyloidosis).
结论:
- 该综述简要概述了2024年具有影响力的心脏病学试验.
- 这些信息对临床医生和心脏病学领域的研究人员来说是有价值的.
更多相关视频
02:47Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
相关概念视频
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...